Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−7.98%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

29.31 0.14 −0.48%
Market cap
$170.3B
P/E
42.2×
Fwd P/E
18.9×
Dividend yield
7.18%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

18.31 21.44 31.68 40.14
P/S ratio
2.26 2.52 2.15 2.56
P/FCF ratio
17.10 18.40 13.47 14.80
P/Operating CF
26.46 61.11 164.35 30.24
P/B ratio
1.63 1.77 1.61 1.82
EV/Sales
3.08 3.34 2.96 3.32
EV/EBITDA
9.25 10.00 9.25 10.48
EV/FCF
23.28 24.32 18.53 19.20
Current Ratio
1.16 1.25 1.27 1.42
Net Debt/EBITDA
11.23 9.10 10.99 9.22
Debt/Equity
0.75 0.71 0.74 0.70
Earnings Yield
5.46% 4.67% 3.16% 2.49%
Free Cash Flow Yield
5.85% 5.43% 7.42% 6.76%
Free Cash Flow per Share
0.79 0.38 0.05 0.84
Book value per Share
15.27 15.89 15.00 15.67
Free Cash Flow
4,503.00 2,179.00 302.00 4,802.00
EV/EBIT
13.53 14.53 13.66 15.47
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026